



Liberty Biopharma Shareholders Approve the Acquisition of HooXi

TSXV – LTY.V

VANCOUVER, August 31, 2018 - **Liberty Biopharma Inc. (TSXV: LTY)** ("Liberty" or the "Company") is pleased to report, at its Special Meeting of Shareholders, that the Company's shareholders voted in favour of the resolution to approve the acquisition of HooXi as described in the Information Circular sent to shareholders, which was dated July 25, 2018.

Approximately 47.7% of the common shares of the Company were represented at the meeting in person or by proxy of which 98.54% were voted in favour of the resolution.

Completion of the acquisition is subject to a number of customary closing conditions including the completion of mutually satisfactory due diligence; completion of the proposed CAD \$2,640,000 private placement; renaming of the Company to HooXi; and receipt of all required TSXV, regulatory, corporate and third party approvals.

About Liberty Biopharma Inc.

Liberty Biopharma is a medical digital technology and biopharmaceutical company active in global strategic partnerships and in-licensing of technologies and assets for rapid growth and high value solutions.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities to be issued in connection with the Transaction have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S promulgated under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward Looking Statements:

Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of Liberty. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to the agreements with HooXi. These statements generally can be identified by use of forward-looking terms such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. These forward-looking statements involve numerous risks and uncertainties and actual results might differ materially from results anticipated in any forward-looking statements.

Important factors that may cause actual results with respect to the Transaction to differ from anticipated results include the ability of the parties to fulfill conditions precedent to the Transaction, the willingness of the shareholders of Liberty and HooXi to approve the Transaction, and whether or not the TSXV and other regulators approve the Transaction. In making the forward-looking statements in this news release, Liberty has applied several material assumptions, including without limitation that the terms of the agreement with HooXi will be acceptable to the TSXV and the shareholders of the Company and HooXi. Liberty does not assume any obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements, other than as required by applicable securities laws.

For further information, please contact:

*Alan Tam, CPA, CA
CFO, Liberty Biopharma Inc.
(604) 377-7575*